US 12,285,417 B2
Methods for treating chronic obstructive pulmonary disease
Christopher Noel Barnes, South San Francisco, CA (US); Glenn D. Crater, South San Francisco, CA (US); Edmund J. Moran, South San Francisco, CA (US); and Srikanth Pendyala, South San Francisco, CA (US)
Assigned to THERA VANCE BIOPHARMA R&D IP, LLC, South San Francisco, CA (US)
Filed by THERAVANCE BIOPHARMA R&D IP, LLC, South San Francisco, CA (US)
Filed on Apr. 21, 2023, as Appl. No. 18/137,922.
Application 18/137,922 is a continuation of application No. 17/953,036, filed on Sep. 26, 2022, abandoned.
Application 17/953,036 is a continuation of application No. 16/555,216, filed on Aug. 29, 2019, granted, now 11,484,531, issued on Nov. 1, 2022.
Claims priority of provisional application 62/724,805, filed on Aug. 30, 2018.
Prior Publication US 2023/0330075 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/444 (2006.01); A61K 9/00 (2006.01); A61K 31/135 (2006.01); A61P 11/06 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 9/0078 (2013.01); A61K 31/135 (2013.01); A61P 11/06 (2018.01); A61K 45/06 (2013.01)] 16 Claims
 
1. A method for treating chronic obstructive pulmonary disease (COPD) in a patient having severe to very severe COPD, the method comprising:
selecting a patient having a percent predicted force expiratory volume in one second of less than about 50 percent; and
selecting a nebulizer as an inhalation delivery device to administer revefenacin, or a pharmaceutically acceptable salt thereof, to the patient,
wherein the patient has a peak inspiratory flow rate of less than about 60 L/min; and
wherein the method comprises administering a pharmaceutical composition comprising an aqueous solution of revefenacin, or a pharmaceutically acceptable salt thereof, to the patient using the nebulizer.